Skip to main content

Table 3 Correlations between angiogenesis-related biomarkers and clinical tumor characteristics (n = 75)

From: Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

(mean ± standard deviation)

p-value※

Sex

Tumor stage*

Histology

EGFR Mutation#

ALK/ROS1 Rearrangement†

Male

Female

Stage I / II

Stage III / IV

Adenocarcinoma

Non-Adenocarcinoma

Found

Not found

Found

Not found

VEGF-A (pg/mL)

326 ± 353

192 ± 231

148 ± 138

318 ± 349

268 ± 309

313 ± 361

254 ± 317

293 ± 326

389 ± 601

275 ± 311

0.053

0.004‡

0.632

0.621

0.774

Angiogenin (ng/mL)

539 ± 172

491 ± 180

473 ± 111

537 ± 188

504 ± 178

577 ± 160

430 ± 161

571 ± 1 64

735 ± 203

513 ± 170

0.174

0.091

0.102

0.061

0.196

Angiopoietin-1 (ng/mL)

49 ± 39

32 ± 23

43 ± 31

44 ± 37

38 ± 31

57 ± 44

35 ± 30

47 ± 37

53 ± 44

43 ± 35

0.055

0.931

0.095

0.139

0.739

MTV (cm3)

56 ± 61

30 ± 46

12 ± 17

57 ± 61

30 ± 38

96 ± 74

32 ± 37

60 ± 62

82 ± 71

45 ± 57

0.065

< 0.001‡

0.108

0.139

0.469

SUVmax

15 ± 8

12 ± 6

9 ± 6

15 ± 7

13 ± 7

18 ± 8

12 ± 7

15 ± 7

10 ± 6

14 ± 8

0.070

0.101

0.112

0.156

0.355

ADC (10− 6 mm2/sec)

1056 ± 296

1137 ± 324

1145 ± 499

876 ± 236

1122 ± 321

975 ± 231

1077 ± 321

1088 ± 301

1064 ± 375

1085 ± 306

0.293

0.190

0.059

0.883

0.931

Ktrans (10− 3 min− 1)

392 ± 556

197 ± 333

283 ± 430

464 ± 675

332 ± 556

302 ± 265

401 ± 676

284 ± 371

633 ± 1011

312 ± 474

0.063

0.310

0.754

0.420

0.638

kep (10− 3 min− 1)

1484 ± 1350

1062 ± 1300

935 ± 532

1455 ± 779

1211 ± 1337

1710 ± 1310

1066 ± 931

1482 ± 1501

2689 ± 3436

1281 ± 1207

0.193

0.029‡

0.163

0.144

0.552

ve (10− 3)

206 ± 192

144 ± 83

286 ± 280

155 ± 97

188 ± 185

176 ± 85

239 ± 253

156 ± 79

135 ± 111

187 ± 167

0.052

0.173

0.722

0.115

0.513

vp (10− 3)

121 ± 99

117 ± 50

114 ± 74

121 ± 88

119 ± 92

120 ± 60

139 ± 118

109 ± 59

75 ± 39

121 ± 86

0.830

0.729

0.984

0.242

0.159

iAUC60 (10− 3)

378 ± 412

266 ± 135

511 ± 622

289 ± 187

350 ± 393

307 ± 127

458 ± 536

276 ± 150

300 ± 285

341 ± 349

0.086

0.165

0.471

0.102

0.831

  1. Abbreviations: MTV = metabolic tumor volume; SUVmax = maximum standardized uptake value; kep = reverse reflux rate constant; Ktrans = volume transfer constant; vp = blood plasma volume fraction; ve = extracellular extravascular volume fraction; ADC = apparent diffusion coefficient; iAUC60 = initial area under the time-to-signal intensity curve at 60 s post enhancement
  2. * Tumor stage was classified by the American Joint Committee on Cancer 8th edition
  3. # EGFR mutation was defined as the presence of an EGFR exon19del or L858R mutation in tumor genomic DNA
  4. † Anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) rearrangement was defined as the presence of an ALK or ROS1 rearrangement in tumor genomic DNA
  5. ※Significance was tested using Student’s t-test
  6. ‡ P-values < 0.05 were considered statistically significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us